Physician profile
Catherine Dalton
NPI 1104899244
$1,446.12
in general payments reported to CMS, 2019-2025
18 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $67.99 · 2021: $42.32 · 2022: $216 · 2023: $113 · 2024: $422 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $320.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $195.61 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $173.48 | 2019-2025 | Farxiga, Breztri |
| Corcept Therapeutics | $167.73 | 2019-2025 | Korlym |
| Lilly USA, LLC | $136.98 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $83.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $70.95 | 2022-2024 | |
| Eisai INC. | $52.07 | 2024 | |
| Merck Sharp & Dohme LLC | $41.78 | 2023-2025 | Capvaxive, Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.85 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $34.38 | 2024-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $22.95 | 2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $22.62 | 2024 | Voquezna |
| Allergan, INC. | $22.00 | 2020 | |
| Pfizer INC. | $20.75 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16.19 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.58 | 2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.